Video Experimental Relacionado

Updated: Sep 10, 2025

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

Avances de las vacunas de ARNm en los cánceres genitourinarios

You-Min Shen¹, Fang-Ning Wan¹, Hua Xu¹

¹Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Shanghai Genitourinary Cancer Institute, Shanghai 200032, China.

Biochimica et biophysica acta. Reviews on cancer

|August 22, 2025

Resumen

La tecnología de ARN mensajero (ARNm) está revolucionando el tratamiento del cáncer, ofreciendo vacunas y terapias personalizadas. Esta revisión explora el ARNm

Área de la Ciencia:

Oncología e Inmunología
Biotecnología y ingeniería genética

Sus antecedentes:

La tecnología del ARN mensajero (ARNm) ha avanzado rápidamente, y la disminución de los costos ha aumentado su uso en intervenciones médicas.
A diferencia de los métodos tradicionales, las vacunas de ARNm aprovechan la secuenciación de próxima generación (NGS) para el diseño individualizado.
La tecnología de ARNm ofrece aplicaciones versátiles en el tratamiento del cáncer, incluida la codificación de antígenos, la administración de citoquinas, la terapia génica y las terapias basadas en células T.

Objetivo del estudio:

Revisar el desarrollo y la aplicación de vacunas de ARNm en cánceres genitourinarios.
Para resumir diversos tipos de ARNm sintéticos y sistemas de entrega eficientes.
Discutir las investigaciones preclínicas y clínicas, los desafíos y las oportunidades futuras en terapias contra el cáncer basadas en ARNm.

Principales métodos:

Revisión de la literatura de estudios preclínicos y clínicos sobre las vacunas de ARNm en cánceres genitourinarios.
Análisis de tipos de ARNm sintéticos, sistemas de administración y estrategias terapéuticas.
Examen de los obstáculos actuales y las perspectivas de futuro en este campo.

Principales resultados:

Los enfoques basados en el ARNm muestran una promesa significativa en los estudios preclínicos de cáncer, y varios avanzan a los ensayos clínicos.
La seguridad y eficacia establecidas de las vacunas de ARNm autorizadas respaldan el creciente interés en las terapias de ARNm.
La tecnología de ARNm está preparada para desempeñar un papel crucial en el futuro del tratamiento del cáncer.

Conclusiones:

La tecnología de ARNm ofrece una plataforma poderosa para desarrollar nuevos tratamientos contra el cáncer, particularmente en los cánceres genitourinarios.
La investigación continua en diversos tipos de ARNm, sistemas de entrega y aplicaciones clínicas es esencial.
Superar los obstáculos actuales desbloqueará todo el potencial de las terapias basadas en ARNm para mejorar los resultados de los pacientes.

Palabras clave:

Nuevo antígeno Cáncer de próstata Carcinoma de las células renales Cáncer urotelial Vacunas de ARNm

Más Videos Relacionados

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles

Published on: August 17, 2022

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Videos de Conceptos Relacionados

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Mechanisms of Retrovirus-induced Cancers

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...

Initiation of Translation

Initiation of Translation

Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...